Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.
暂无分享,去创建一个
J. Lancet | L. Moscinski | W. Fulp | E. Padron | Ling Zhang | K. Zuckerman | R. Komrokji | Y. Suleiman | S. Dalia | J. Bowers | J. Liu
[1] Daniel B. Aruch,et al. Contemporary approach to essential thrombocythemia and polycythemia vera , 2016, Current opinion in hematology.
[2] T. Barbui,et al. New and treatment‐relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera , 2015, American journal of hematology.
[3] J. Smith-Gagen,et al. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011 , 2015, Journal of Cancer Research and Clinical Oncology.
[4] P. de Paepe,et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations , 2015, Haematologica.
[5] V. Bhatt. Leukemic transformation in essential thrombocythemia. , 2014, Future oncology.
[6] T. Barbui,et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. , 2014, Blood.
[7] M. Björkholm,et al. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? , 2014, Best practice & research. Clinical haematology.
[8] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[9] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[10] R. Kralovics,et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.
[11] P. Campbell,et al. How I treat essential thrombocythemia. , 2011, Blood.
[12] P. Johansson,et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera , 2011, European journal of haematology.
[13] Juergen Thiele,et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms , 2009, Cancer.
[14] A. Tefferi,et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance , 2009, European journal of haematology.
[15] P. Campbell,et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Green,et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. , 2008, The New England journal of medicine.
[17] C. Pascutto,et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients , 2008, Haematologica.
[18] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[19] A. Tefferi,et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients , 2007, Leukemia.
[20] R. Mesa,et al. JAK2V617F and leukemic transformation in myelofibrosis with myeloid metaplasia , 2006 .
[21] D. Larson,et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. , 2006, Mayo Clinic proceedings.
[22] J. D. van der Walt,et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.
[23] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[24] T. Barbui,et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial , 2000, British journal of haematology.
[25] A. Green,et al. 7 Molecular genetics and cytogenetics of myeloproliferative disorders , 1998 .
[26] T. C. Liu,et al. Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndrome. , 1998, Blood.
[27] G. Tobelem. 9 Essential thrombocythaemia , 1989 .
[28] Peter J Campbell,et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. , 2008, Blood.
[29] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.
[30] R. Fonseca,et al. A long-term retrospective study of young women with essential thrombocythemia. , 2001, Mayo Clinic proceedings.
[31] Arturo Pereira,et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. , 1991, Acta haematologica.